William Blair Raises Earnings Estimates for Exact Sciences

Key Points

• William Blair has revised its FY2025 earnings per share (EPS) estimate for Exact Sciences from $0.22 to $0.36, while the current consensus estimate stands at ($0.58) per share.
• Various analysts are providing mixed ratings on Exact Sciences, with upgrades and downgrades in price targets, resulting in a consensus rating of "Moderate Buy".
• In the latest quarterly report, Exact Sciences beat earnings expectations significantly, reporting $0.22 EPS against a consensus estimate of (0.02), along with a 16% year-over-year revenue increase.

Exact Sciences Corporation (NASDAQ:EXAS - Free Report) - Analysts at William Blair upped their FY2025 EPS estimates for Exact Sciences in a report issued on Wednesday, September 10th. William Blair analyst A. Brackmann now forecasts that the medical research company will post earnings per share of $0.36 for the year, up from their prior estimate of $0.22. The consensus estimate for Exact Sciences' current full-year earnings is ($0.58) per share. William Blair also issued estimates for Exact Sciences' Q4 2025 earnings at $0.20 EPS.

A number of other analysts have also recently commented on the company. Evercore ISI lowered their price target on Exact Sciences from $68.00 to $64.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. Wall Street Zen upgraded Exact Sciences from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. BTIG Research reduced their price objective on shares of Exact Sciences from $65.00 to $60.00 and set a "buy" rating for the company in a research report on Tuesday, August 12th. Zacks Research downgraded Exact Sciences from a "strong-buy" rating to a "hold" rating in a research report on Thursday, September 4th. Finally, Barclays dropped their price objective on shares of Exact Sciences from $65.00 to $55.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $68.05.

Exact Sciences Stock Performance

Shares of Exact Sciences stock opened at $53.94 on Monday. The company has a 50 day moving average price of $48.86 and a 200 day moving average price of $49.30. The firm has a market capitalization of $10.21 billion, a P/E ratio of -9.93, a PEG ratio of 4.98 and a beta of 1.05. Exact Sciences has a 52 week low of $38.81 and a 52 week high of $72.83. The company has a quick ratio of 2.56, a current ratio of 2.89 and a debt-to-equity ratio of 0.94.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its earnings results on Wednesday, August 6th. The medical research company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.24. The business had revenue of $811.09 million for the quarter, compared to analysts' expectations of $774.43 million. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The business's revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.09) EPS.

Institutional Investors Weigh In On Exact Sciences

A number of hedge funds have recently bought and sold shares of EXAS. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Exact Sciences in the 1st quarter valued at $34,000. Cerity Partners LLC grew its position in Exact Sciences by 24.0% in the 1st quarter. Cerity Partners LLC now owns 33,598 shares of the medical research company's stock valued at $1,454,000 after buying an additional 6,508 shares during the last quarter. Teacher Retirement System of Texas acquired a new position in shares of Exact Sciences during the first quarter worth about $1,171,000. GAMMA Investing LLC increased its position in Exact Sciences by 15.5% during the 1st quarter. GAMMA Investing LLC now owns 4,243 shares of the medical research company's stock worth $184,000 after purchasing an additional 569 shares during the period. Finally, Merit Financial Group LLC raised its position in Exact Sciences by 110.0% in the first quarter. Merit Financial Group LLC now owns 8,799 shares of the medical research company's stock worth $381,000 after acquiring an additional 4,609 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company's stock.

Insider Activity at Exact Sciences

In related news, Director James Edward Doyle sold 1,485 shares of Exact Sciences stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $42.02, for a total value of $62,399.70. Following the completion of the transaction, the director owned 59,962 shares in the company, valued at approximately $2,519,603.24. The trade was a 2.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.20% of the company's stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.